Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects. (1st September 2020)

• Record Type: Journal Article
• Authors: Sharun, Khan; Tiwari, Ruchi; Iqbal Yatoo, Mohd.; Patel, Shailesh Kumar; Natesan, Senthilkumar; Dhama, Jaideep; Malik, Yashpal S.; Harapan, Harapan; Singh, Raj Kumar; Dhama, Kuldeep
• Is Part Of: Expert opinion on biological therapy. Volume 20:Number 9(2020)
• Page Start: 1033
• Page End: 1046
• Publication Date: 2020-09-01
• Subjects: COVID-19 -- SARS-CoV-2 -- coronavirus -- immunotherapeutics -- immunoglobulin -- convalescent plasma -- neutralizing antibodies -- monoclonal antibodies; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2020.1796963
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction: Coronavirus disease 2019 (COVID-19) has spread to several countries globally. Currently, there is no specific drug or vaccine available for managing COVID-19. Antibody-based immunotherapeutic strategies using convalescent plasma, monoclonal antibodies (mAbs), neutralizing antibodies (NAbs), and intravenous immunoglobulins have therapeutic potential. Areas covered: This review provides the current status of the development of various antibody-based immunotherapeutics such as convalescent plasma, mAbs, NAbs, and intravenous immunoglobulins against COVID-19. The review also highlights their advantages, disadvantages, and clinical utility for the treatment of COVID-19 patients. Expert opinion: In a pandemic situation such as COVID-19, the development of new drugs should focus on and expedite the strategies where safety and efficacy are proven. Antibody-based immunotherapeutic approaches such as convalescent plasma, intravenous immunoglobulins, and mAbs have a proven record of safety and efficacy and are in use for decades. Some of them are already being used to manage COVID-19 patients and found to be useful. However, the mAbs with virus neutralization potential is the need of the hour during this COVID-19 pandemic to be more specific and virus targeted. The research and investment need to be accelerated to bring them into clinical use for prophylactic and therapeutic purposes against COVID-19.